Arcus Biosciences (RCUS) Q4 FY25 earnings call

Arcus Biosciences is advancing casdatifan as a best-in-class HIF-2 alpha inhibitor for clear cell RCC, demonstrating superior efficacy in late-line monotherapy and pursuing a TKI-free frontline strategy. The company is also developing an immunology portfolio with two programs expected to enter the clinic in late 2026 or early 2027. Arcus maintains a strong financial position, with cash and investments providing a runway into 2028, and anticipates several key data readouts and Phase III initiations in the coming year.